Neurocrine delays US Parkinson’s drug launch amid COVID disruptionThe FDA has approved Ongentys, an oral Parkinson’s Disease drug from US biotech Neurocrine Biosciences, which can be added to prolong the effects Share XNeurocrine delays US Parkinson’s drug launch amid COVID disruptionhttps://pharmaphorum.com/news/neurocrine-delays-us-parkinsons-drug-launch-amid-covid-disruption/